WEBULL
News
CRIS
1.010
-2.88%
-0.030
Weekly Report: what happened at CRIS last week (1222-1226)?
Weekly Report · 1d ago
Weekly Report: what happened at CRIS last week (1215-1219)?
Weekly Report · 12/22 09:52
CURASIGHT ANNOUNCES SUCCESSFUL DOSING OF FIRST PATIENT IN PHASE 1 TRIAL WITH UTREAT® IN BRAIN CANCER
Reuters · 12/18 18:46
Weekly Report: what happened at CRIS last week (1208-1212)?
Weekly Report · 12/15 09:57
After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying
NASDAQ · 12/11 04:49
Curis’s Promising Clinical Developments and Strategic Trials Justify Buy Rating
TipRanks · 12/09 20:05
Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study
Reuters · 12/09 13:01
CURIS PROVIDES UPDATED DATA FROM ITS FRONTLINE AML TRIPLET STUDY
Reuters · 12/09 13:00
Promising Early Data from Curis’s Emavusertib Study Supports Buy Rating
TipRanks · 12/09 11:26
Weekly Report: what happened at CRIS last week (1201-1205)?
Weekly Report · 12/08 09:56
Weekly Report: what happened at CRIS last week (1124-1128)?
Weekly Report · 12/01 09:53
Weekly Report: what happened at CRIS last week (1117-1121)?
Weekly Report · 11/24 09:57
Weekly Report: what happened at CRIS last week (1110-1114)?
Weekly Report · 11/17 09:57
Curis Reports Promising Clinical Data for Emavusertib in CNS Lymphoma at SNO Meeting
Reuters · 11/14 14:26
Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)
TipRanks · 11/12 16:00
Curis’s Strategic Clinical Advancements and Promising Data Drive Buy Rating
TipRanks · 11/11 21:16
Weekly Report: what happened at CRIS last week (1103-1107)?
Weekly Report · 11/10 09:55
Curis Inc. Earnings Call: Clinical Progress and Financial Gains
TipRanks · 11/09 00:28
Curis anticipates initial CLL proof-of-concept study data at ASH 2026 while advancing PCNSL and AML programs
Seeking Alpha · 11/07 18:57
Curis Inc. Advances Cancer Trials with Promising Results
TipRanks · 11/07 05:40
More
Webull provides a variety of real-time CRIS stock news. You can receive the latest news about Curis through multiple platforms. This information may help you make smarter investment decisions.
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins.